Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis.
10.1007/s11684-021-0827-8
- Author:
Yaru TIAN
1
;
Hairong TIAN
1
;
Xiaoyang ZHAI
1
;
Hui ZHU
2
;
Jinming YU
3
Author Information
1. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, 250117, China.
2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, 250117, China. drzhuh@126.com.
3. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, 250117, China. sduyujinming@163.com.
- Publication Type:Journal Article
- Keywords:
advanced non-small-cell lung cancer;
bevacizumab;
elderly patient;
overall survival;
toxicity
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*;
Bevacizumab/adverse effects*;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Humans;
Lung Neoplasms/drug therapy*;
Pemetrexed/adverse effects*;
Platinum/therapeutic use*;
Retrospective Studies;
Treatment Outcome
- From:
Frontiers of Medicine
2022;16(4):610-617
- CountryChina
- Language:English
-
Abstract:
Bevacizumab, an anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC (ns-NSCLC). However, the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation. Thus, 59 patients were included in the present retrospective study, 22 patients in the bevacizumab plus pemetrexed and platinum (B + PP) group, and 37 patients in the pemetrexed and platinum (PP) group. For the entire cohort of patients, the median OS was 33.3 months, and the 1-year and 2-year overall survival rates were 88.5% and 67.8%, respectively. The median OS and 1-year and 2-year OS rates were 20.5 months, 70.3% and 0%, respectively, in the B + PP group and 33.4 months, 97.0% and 89.4%, respectively, in the PP group (P < 0.001). The incidence of grade ⩾ 3 adverse events was higher in the B + PP group than in the PP group (27.3% vs. 10.8%, respectively; P = 0.204). Univariate and multivariate analyses suggested that the receipt of ⩾ 5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS, whereas the addition of bevacizumab was an unfavorable prognostic factor. With increased toxicities, the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.
